Article Today, Hyderabad: A major step in dengue prevention, the Indian Council of Medical Research (ICMR) has launched one of the country’s largest clinical trials to combat dengue. Over 10,000 volunteers across India are participating in this extensive study. The trial aims to test the safety, efficacy, and immune response of a single-dose vaccine named DengiAll.
Trials Underway in 20 Medical Centres
The trials are being conducted in 20 research centres across the country. Leading institutions in Karnataka and Telangana are actively involved. These include JSS Medical College and Hospital in Mysuru, Bangalore Medical College and Research Institute in Bengaluru, and AIIMS Bibinagar near Hyderabad. Each centre is handling trials with strict medical protocols and trained staff.
70% of the Trial Already Completed
According to ICMR, more than 70% of the trials have already been completed successfully. Preliminary observations are encouraging. Researchers are closely monitoring volunteers for side effects and immune response. If final results are positive, this vaccine could offer protection against all four dengue virus strains.
Significant Funding to Support Research
ICMR has allocated substantial funds to each centre. On average, each site is receiving between ₹1.3 crore and ₹1.5 crore. This funding is being used for infrastructure, testing equipment, staff training, and data analysis. With adequate resources, scientists believe the trial will maintain global clinical standards.
A Ray of Hope For Dengue Sufferers
Dengue remains a serious health threat in India, especially during monsoons. Thousands fall ill every year, and several lose their lives. A safe and effective vaccine could reduce hospitalizations and deaths significantly. Medical experts view DengiAll as a potential game-changer in India’s fight against vector-borne diseases.
Next Steps After Trial Completion
Once the trial concludes, the data will undergo rigorous scientific review. If approved by drug regulators, DengiAll could be made available to the public within the next two years. ICMR plans to collaborate with vaccine manufacturers for mass production and affordable pricing.
Hope Rooted in Science
This clinical trial reflects India’s growing strength in medical research. With coordinated efforts and global partnerships, experts believe India can lead in tropical disease prevention. For millions at risk of dengue, DengiAll offers renewed hope for a healthier future.
